Pharmaceuticals
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia
This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs inChina. ARVN003 is expected to be the first approved drug for presbyopia inChina. SHANGHAI, July 4, 2022 /PRNew...
2022-07-04 22:14
2239
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...
2022-07-04 13:34
1796
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment ofPaul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," s...
2022-07-01 22:00
4876
Fosun's Businesses Shows Strong Recovery Momentum as Consumption Regains Vitality and Tourism Industry Continues to Recover
HONG KONG, June 30, 2022 /PRNewswire/ -- The Bund Finance Center (BFC) in Shanghai officially resumed dine-in services at restaurants starting from 29 June. At present, Fosun's businesses and shopping centers inShanghai, including the BFC, Yuyuan Tourist Mart, Forte Woli City, and Orstar City Zhe...
2022-06-30 20:16
3699
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm...
2022-06-30 10:41
1534
Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
* Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing * China's first immunotherapy bi-specific antibody approved for marketing * A phase III trial of Cadonilimab combined with platinum-based chemotherapy +/- bevacizumab for the first-line treatment ...
2022-06-29 20:14
1778
Sanofi Enters into a Partnering Agreement with Health2Sync
Paving the Way for Digital Therapeutics in Diabetes TAIPEI and TOKYO, June 27, 2022 /PRNewswire/ -- Sanofi K.K. (Head office: Shinjuku-ku,Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync. (Head office: Taito-ku,Tokyo; CEO: Ed Deng) have entered into a partnering agreement ...
2022-06-28 11:00
1732
Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application
SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance nu...
2022-06-26 08:00
3507
Sanyou Biopharmaceuticals forged strategic partnership with Dragon Sail Pharmaceutical to upgrade integrated innovative antibody drug R&D
SHANGHAI, June 24, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, aCDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture servic...
2022-06-25 08:00
4877
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patients with idiopathic pulmonary fibrosis - Daewoong Pharmaceutical to start a multinational phase 2 clinical trial for DWN12088 in September SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong...
2022-06-24 21:00
3341
I-Mab Receives Top Rankings in Five Categories by Institutional Investor
GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies i...
2022-06-23 20:00
1371
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan , June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winne...
2022-06-19 10:30
2944
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatmen...
2022-06-17 20:00
3591
111, Inc. Announces First Quarter 2022 Unaudited Financial Results
SHANGHAI, June 16, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the first quart...
2022-06-16 15:58
4028
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner Morpho...
2022-06-15 22:37
2388
J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria
SEOUL, South Korea, June 14, 2022 /PRNewswire/ -- J INTS BIO announced that it
will be presenting the preclinical results of its NSCLC candidate 'JIN-A02' at
the upcoming 2022 IASLC World Conference on Lung Cancer, to be held inVienna,
Austria from 6th to 9th August.
2022-06-14 22:00
1003
Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress
SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress inJune 22-26, 2022 (the EASL meeting). The recently completed phase 1b stu...
2022-06-14 20:00
1081
Telix and Invicro Advance AI Partnership
MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...
2022-06-14 19:00
1864
Kintor Pharma and Etana's Collaboration on Pruxelutamide's COVID-19 Project Awarded with Belt and Road Innovation Project and Fund Support from the Science and Technology Department of Jiangsu Province
SUZHOU, China, June 14, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that its "clinical trial cooperative research and development and ov...
2022-06-14 12:35
1828
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
MELBOURNE, Australia and INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), is now available at selected pharmacies in ...
2022-06-13 19:11
1918
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2931
